Skip to main content

Lipocine Inc.

LPCN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001535955

No open-market purchases or sales by Lipocine Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −11 vs. previous quarter
36
13F valueReported value at the end of Q2 2026
$7.63M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding LPCN, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding LPCN at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Lipocine Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 7, 2026 (view filing)Apr 7Same dayHiguchi John W.DirectorPPurchase+40.0K$2.03+$81.2K+24.4%203.8K after
Apr 6, 2026 (view filing)Apr 6Same dayHiguchi John W.DirectorPPurchase+123.0K$2.05+$252.2K+301.5%163.8K after
Apr 6, 2026 (view filing)Apr 6Same dayPatel Mahesh V.Chief Executive OfficerPPurchase+25.0K$2.03+$50.8K+18.4%160.7K after
Apr 2, 2026 (view filing)Apr 2Same dayPatel Mahesh V.Chief Executive OfficerPPurchase+25.0K$2.02+$50.5K+22.6%135.7K after
May 25, 2023 (view filing)May 25Same dayPatel Mahesh V.CEO and PresidentPPurchase+8.71K$5.03+$43.8K+8.8%107.4K after
Mar 24, 2023 (view filing)5:28 PM ETMar 24Same dayPatel Mahesh V.CEO and PresidentPPurchase+150.0K$0.32+$48.0K+9.8%1.68M after
Mar 20, 2023 (view filing)6:51 PM ETMar 20Same dayOno Richard DanaDirectorPPurchase+4.00K$0.34+$1.36K+39.5%14.1K after
Mar 17, 2023 (view filing)4:31 PM ETMar 17Same dayPatel Mahesh V.CEO and PresidentPPurchase+50.0K$0.33+$16.5K+3.4%1.53M after
Nov 28, 2022 (view filing)4:33 PM ETNov 226 daysLatePapapetropoulos SpyridonDirectorPPurchase+21.7K$0.47+$10.2KNew position21.7K after
Nov 14, 2022 (view filing)3:58 PM ETNov 14Same dayPatel Mahesh V.CEO and PresidentPPurchase+75.0K$0.39+$29.3K+5.3%1.48M after

Top 10 13F holders, Q2 2026

The largest institutional positions in Lipocine Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 36 holders
Institutions holding LPCN in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Squadron Capital Management LLC810,000$2.07M0.71%+360,000+80.0%Added
Ikarian Capital, LLC508,556$1.30M0.21%00.0%Unchanged
Eversept Partners, LP294,989$755.2K0.04%00.0%Unchanged
Vanguard Capital Management LLC230,823$590.9K0.00%+30,155+15.0%Added
Acadian Asset Management LLC170,417$435.0K0.00%+170,417New
Boothbay Fund Management, LLC140,487$359.6K0.01%00.0%Unchanged
Jane Street Group, LLC95,227$243.8K0.00%+75,200+375.5%Added
BlackRock, Inc.89,272$228.5K0.00%00.0%Unchanged
Two Sigma Investments, LP84,887$217.3K0.00%+51,137+151.5%Added
Citadel Advisors LLC81,221$207.9K0.00%+52,133+179.2%Added